Daniel Webster, dWeb.News Publisher
DUBLIN, Nov. 25, 2021 /PRNewswire/ — The “IgA Nephropathy (IgAN) – Market Insights, Epidemiology, and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, United Kingdom), and Japan. IgA nephropathy’s market size in the seven major markets was USD 109.3 million in 2020.
The report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted IgA Nephropathy market size from 2018 to 2030, segmented by seven major markets. This report covers the current IgA Nephropathy treatment practices/algorithms, market drivers, market obstacles, and unmet medical need to curate the most promising opportunities. It also assesses market potential and evaluates the market’s underlying potential.
Study Period: 2018-2030
The IgA nephropathy epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. This report examines the views and studies of leading opinion leaders to help identify the causes and trends. This section of the report provides information about the patient pool, trends and assumptions.
Epidemiology: Key Findings
The total prevalent cases of IgA nephropathy in the 7MM are increasing during the study period, i.e., 2018-2030.
The disease epidemiology covered in the report provides historical and forecasted IgA nephropathy epidemiology segmented as the prevalence of IgA nephropathy, gender-specific cases of IgA nephropathy, and age-specific cases of IgA nephropathy. The report includes the prevalent scenario of IgA nephropathy in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
The epidemiology segment also provides the IgA Nephropathy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total number of prevalent cases of IgA Nephropathy associated in 7MM countries was 377,829 in 2020.
The report’s drug chapters enclose the detailed analysis of IgA nephropathy early-stage (Phase I, II, and III) pipeline drugs. It provides information on IgA nephropathy’s clinical trials, expressive pharmacological actions, agreements and collaborations, patent details, approvals and patent details, the advantages and disadvantages of each drug and the most recent news releases.
NEFECON: Calliditas Therapeutics AB
Nefecon is a patented oral formulation of a potent and well-known active substance – budesonide – for targeted release. According to the most common pathogenesis models, the formulation is intended to deliver the drug to the Peyer’s patch area of the lower small intestinale. It is derived using the TARGIT technology which allows the drug to pass through the stomach without being absorbed. The substance is released in a pulse-like manner only once it reaches lower small intestine.
Sparsentan: Travere Therapeutics Inc.
Sparsentan is a first-in-class, orally active, single-molecule that functions as a high-affinity dual-acting antagonist of both endothelin type A (ETA) and angiotensin II subtype 1 (AT1) receptors which are associated with kidney disease progression.
According to the publisher, the IgA Nephropathy market in 7MM is expected to grow in the study period 2018-2030.
Treatment options, therefore, center on modulating downstream immune and inflammatory events in the glomerulus and tubulointerstitium. Many of the current treatments are generic for other chronic glomerular diseases, including renin-angiotensin blocking, blood pressure control, and reduction of proteinuria.
There is consensus that supportive treatment with renin-angiotensin blockade and tight BP control should be the initial treatment. There is still a small subset of patients who have persistent proteinuria, despite receiving supportive treatment. These patients are at risk for developing progressive disease. There is no consensus as to whether corticosteroids and other immunosuppressive drugs reduce the risk of progression while maintaining acceptable toxicities.
This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018-2030. This analysis includes the IgA nephropathy market, uptake of drugs by patients, and sales.
This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
The report provides insights into the therapeutic candidate in Phase I, II, and III stages. The report also examines IgA nephropathy key actors involved in the development of targeted therapeutics. Calliditas Therapeutics AB and Travere Therapeutics are the major players. Omeros Corporation, Novartis Pharmaceuticals and Omeros Corporation are also key players.
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for IgA nephropathy emerging therapies.
Approaching reimbursement proactively can positively impact both during the early stages of product development and well after product launch. We will be discussing reimbursement in order to identify market opportunities and economically appealing indications. The ability to choose the most affordable markets can be crucial for price and business strategy when working with limited resources.
The high treatment costs, including chemo and other therapies, affect patients’ affordability and access to these treatment options. The drug’s market access is affected by reimbursement. The decision to reimburse is often based on the drug’s price in relation to the benefits it provides for patients.
The disease advocacy groups working in the area of IgA Nephropathy helps patients with medical billing, insurance coverage, and reimbursement issues. People who are unable to afford their medication can also get financial assistance from the government and pharmaceutical companies. Durand-Zaleski et. al. used to perform a cost analysis. (1996) to evaluate three possible immunoglobulin (IgG) treatment protocols for end-stage renal disease due to IgA nephropathy. The cost analysis was done from the perspective of the health care delivery system. The baseline strategy was IgG treatment in absence. There were three options for IgG treatment currently under trial. All three included high intravenous IgG doses. Protocol 1 used intramuscular IgG injections alone, protocol 2 had intramuscular injections plus intravenous injections, while protocol 3 used intravenous injections. The treatment costs included outpatient hospital costs and immunoglobulins. There was no savings from kidney dialysis. The bottom line for the healthcare system is a net savings of USD 233,000, USD 213,000, or USD 83,000, depending on the protocol chosen. Costs were not calculated taking into account psychological and physical health benefits.
To keep up with current market trends, the publisher takes KOLs and SMEs’ opinions working in the IgA nephropathy domain through primary research to fill the data gaps and validate our secondary research. Their opinions help to understand and validate emerging treatments or IgA Nephropathy market patterns. This information will assist clients in identifying unmet market needs and the market’s overall picture.
Competitive Intelligence Analysis
The publisher performs a Competitive and Market Intelligence analysis of the IgA Nephropathy Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The availability of data is the only determinant of whether the analysis will be included.
Scope of the Report
The report covers the descriptive overview of IgA nephropathy, explaining its causes, signs and symptoms, physiology, and currently available therapies.
Comprehensive insight is provided into the IgA nephropathy epidemiology and treatment in the 7MM.
Additionally, an all-inclusive account of both the current and emerging therapies for IgA nephropathy is provided, along with the assessment of new therapies, which will impact the current treatment landscape. The report includes a detailed analysis of the IgA market. It also covers drug outreach in the 7MM.
The report provides an edge while developing business strategies by understanding trends shaping and driving the global IgA nephropathy market.
In the coming years, the IgA nephropathy market is set to change due to the rising awareness of the disease and the favorable environment for new anti-infective modalities, which would expand the market’s size to enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence IgA nephropathy R&D. New approaches are being developed to improve the condition.
Major players are involved in developing therapies for IgA nephropathy. IgA Nephropathy will see a significant increase in the number of new therapies.
The in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Reasons to Buy
The report will help in developing business strategies by understanding trends shaping and driving the IgA nephropathy market. To understand the market for IgA nephropathy and to identify market barriers and drivers.
Organize sales and marketing efforts by identifying the best opportunities for IgA nephropathy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
Organize sales and marketing efforts by identifying the best opportunities for the IgA nephropathy market. To understand the market for IgA nephropathy, organize sales and marketing efforts.
Calliditas Therapeutics AB
Travere Therapeutics, Inc.
Chinook Therapeutics, Inc.
Vera Therapeutics, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/56w1tq
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
For more dWeb.News Business News: https://dweb.news/news-sections/business-news/
The post BUSINESS: IgA Nephropathy Market Trends And Epidemiology 2018-2030 With A Detailed Analys Of Emerging Drugs NEFECON And Sparsentan (Travere Therapeutics), appeared first on dWeb.News dWeb.News from Daniel Webster Publisher dWeb.News – dWeb Local Tech News and Business News